Grifols
 |
|
| Sociedad Anónima | |
| Traded as | BMAD: GRF NASDAQ: GRFS |
| Industry | Pharmaceuticals, chemicals |
| Founded | 1940 |
| Headquarters | Barcelona, Spain |
|
Key people
|
Víctor Grifols (Chairman and CEO) |
| Products | Plasma derivatives, in vitro diagnostic products, non-biological products for laboratories and hospitals |
| Revenue |  €2,741.732 million (2013)[1] |
| €736.1 million (2013)[1] |
|
| Profit | €345.6 million (2013)[1] |
| Total assets | €7,276.1 million (june 2014)[1] |
| Total equity | €2,107.2 million (end 2013)[1] |
|
Number of employees
|
11,779 (end 2013)[1] |
| Website | www.grifols.com |
Grifols, S.A. (Catalan: [ɡɾiˈfɔɫs]) is a Spanish multinational pharmaceutical and chemical company. Principally a producer of blood plasma-based products, a field in which it is the European leader and largest worldwide,[2][3] the company also supplies devices, instruments and reagents for clinical testing laboratories.
Main products
Grifols is the major world supplier of IVIG, albumin, Factor VIII and other plasma-derived products.
Main operations
In 2007 the company had 3.6 million litres per year of blood fractionation capacity from three plants, one at Parets del Vallès near Barcelona in Spain (2.1 million litres per year), another in Los Angeles (1.5 million litres but being expanded to 2.2 million litres), and a site in Clayton,NC. In the United States the company owns 153 plasmapheresis centres, where it collects around 5.8 million litres of plasma per year.
Ownership
Grifols was listed on the Madrid Stock Exchange in May 2006.[4] The stock became part of the IBEX 35 index in January 2008.
History
Grifols was founded in 1940 in Barcelona by Dr José A. Grifols Roig, a hematologist and scientist. Dr Grifols was the first researcher to publish the plasmapheresis procedure in 1951. The company introduced its liquid IVIG product into the European market in the mid-1990s. In 2003 the company acquired certain assets of the Los Angeles-based Alpha Therapeutic as the basis of its American expansion.[citation needed]
On June 1, 2011, a year after announcing the $4 billion deal, Grifols completed a takeover of Talecris Biotherapeutics, headquartered in Research Triangle Park in North Carolina, with over 2000 employees.[5]
Grifols acquired the blood transfusion diagnostics unit from Novartis in 2013 as a "platform for global expansion".[3] This unit is based in Emeryville, California and was a part of Chiron acquired by Novartis in 2006.[3]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ 3.0 3.1 3.2 Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
